---
id: 186
title: Antimicrobial Stewardship Core Principles
category: stewardship
subcategory: principles
tags: [stewardship, ASP, de-escalation, narrow-spectrum, duration]
difficulty: medium
---

## Question

What are the core principles of antimicrobial stewardship? Use **"Right Drug, Right Dose, Right Duration + De-escalate, Avoid Unnecessary Use"** framework.

## Answer

### **Core Strategies:**

**1. Prospective Audit and Feedback:**
- **Review broad-spectrum antibiotics** (carbapenems, vancomycin, anti-pseudomonal agents)
- **Provide recommendations** to prescribers (de-escalation, dose optimization, stop if not indicated)

**2. Formulary Restriction and Preauthorization:**
- **Restrict high-risk/broad-spectrum agents** (require ID approval)
- **Examples:** Fluoroquinolones, carbapenems, daptomycin, linezolid, echinocandins

**3. De-escalation:**
- **Start broad empirically** (cover likely pathogens)
- **Narrow based on cultures/susceptibilities** (switch to targeted therapy)
- **Example:** Vancomycin + cefepime (empiric) → cefazolin (MSSA bacteremia)

**4. IV-to-PO Conversion:**
- **Switch to oral** when clinically stable (hemodynamically stable, tolerating PO, functioning GI tract)
- **Agents with excellent PO bioavailability:** Fluoroquinolones, linezolid, TMP-SMX, metronidazole, fluconazole, voriconazole, doxycycline, clindamycin

**5. Dose Optimization:**
- **Ensure adequate dosing** (based on PK/PD, renal/hepatic function, site of infection)
- **Examples:**
  - **Vancomycin:** Target AUC/MIC 400-600 (or trough 15-20 for serious infections)
  - **β-lactams:** Extended/continuous infusions for severe infections (maximize time above MIC)
  - **Daptomycin:** ≥8-10 mg/kg for bacteremia/endocarditis (NOT 6 mg/kg)

**6. Optimize Duration:**
- **Avoid prolonged courses** (increased resistance, *C. difficile* risk)
- **Evidence-based durations:**
  - **Uncomplicated UTI:** 3 days (women), 5-7 days (men/pyelonephritis)
  - **Community-acquired pneumonia:** 5 days (if clinically stable)
  - **Skin/soft tissue infection:** 5-7 days (if source controlled, cellulitis)
  - **Intra-abdominal infection:** 4-7 days (if source controlled)
  - **Bacteremia:** Varies (7-14 days for Gram-negatives, 14-42 days for *S. aureus* depending on complications)

**7. Avoid Unnecessary Use:**
- **Do NOT treat:** Asymptomatic bacteriuria (except pregnancy, pre-urologic procedure), colonization, viral infections (bronchitis, URI)
- **Stop if no infection** (negative cultures + no clinical evidence)

### **Key Metrics:**

**Process Measures:**
- **Days of therapy (DOT) per 1000 patient-days**
- **Defined daily dose (DDD) per 1000 patient-days**
- **Compliance with guidelines**

**Outcome Measures:**
- **Antimicrobial resistance rates** (*C. difficile* incidence, MRSA, MDR Gram-negatives)
- **Mortality, length of stay**
- **Cost savings**

### **Behavioral Interventions:**

**Antibiotic "Time-Out" (48-72 Hours):**
- **Reassess need** for antibiotics at 48-72h
- **Questions:** Is infection confirmed? Are cultures back? Can we de-escalate/stop?

**Education:**
- **Prescriber education** (guidelines, resistance patterns, stewardship principles)
- **Audit and feedback** (personalized data on prescribing patterns)

## Key Points

### **De-escalation = Key:**
- **Start broad → narrow based on cultures**
- **Example:** Vanc + cefepime → nafcillin (MSSA), ceftriaxone (ESBL-negative *E. coli*)

### **Shorter is Often Better:**
- **CAP:** 5 days (if clinically stable)
- **Uncomplicated intra-abdominal infection:** 4 days (if source controlled)
- **Cellulitis:** 5-7 days (if improving)

### **Avoid Treating Asymptomatic Bacteriuria:**
- **Only treat if:** Pregnant OR pre-urologic procedure
- **Do NOT treat:** Elderly, chronic Foley, spinal cord injury (unless symptomatic)

### **IV-to-PO Conversion:**
- **High bioavailability agents:** Fluoroquinolones, linezolid, fluconazole, metronidazole, TMP-SMX
- **Criteria:** Hemodynamically stable, tolerating PO, functioning GI tract

### **Clinical Pearls:**
- **Prospective audit and feedback** = most effective stewardship intervention
- **De-escalate based on cultures** (start broad → narrow)
- **Optimize duration** (avoid prolonged courses)
- **IV-to-PO switch** when clinically stable (high bioavailability agents)
- **Avoid treating colonization, asymptomatic bacteriuria, viral infections**

## Sources

- [IDSA/SHEA: Antimicrobial Stewardship Guidelines 2024]
- [CDC: Core Elements of Hospital Antibiotic Stewardship 2024]

## Media

N/A
